BMS-247550 in Treating Patients With Advanced Pancreatic Cancer

This study has been completed.
Sponsor:
Collaborator:
Information provided by:
National Cancer Institute (NCI)
ClinicalTrials.gov Identifier:
NCT00016965
First received: June 6, 2001
Last updated: June 20, 2013
Last verified: April 2003
  Purpose

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.

PURPOSE: Phase II trial to study the effectiveness of BMS-247550 in treating patients who have advanced pancreatic cancer.


Condition Intervention Phase
Pancreatic Cancer
Drug: ixabepilone
Phase 2

Study Type: Interventional
Study Design: Primary Purpose: Treatment
Official Title: A Phase II Trial of Epothilone B Analogue BMS-247550 (NSC #710428) Every 21 Days in Patients With Advanced Pancreas Cancer

Resource links provided by NLM:


Further study details as provided by National Cancer Institute (NCI):

Study Start Date: July 2001
Study Completion Date: April 2006
Detailed Description:

OBJECTIVES:

  • Determine the 6-month survival rate and time to treatment failure in patients with advanced pancreatic adenocarcinoma treated with BMS-247550.
  • Determine the frequency and severity of toxic effects of this drug in these patients.
  • Determine the complete and partial response in those patients with measurable disease treated with this drug.
  • Determine the pharmacokinetic profile of this drug in these patients.

OUTLINE: This is a multicenter study.

Patients receive BMS-247550 IV over 3 hours on day 1. Courses repeat every 21 days in the absence of unacceptable toxicity or disease progression.

Patients are followed every 6 months for 2 years and then annually until 3 years after registration.

PROJECTED ACCRUAL: A total of 25-55 patients will be accrued for this study.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

DISEASE CHARACTERISTICS:

  • Histologically or cytologically confirmed advanced pancreatic adenocarcinoma

    • Distant metastases OR
    • Locoregional disease that has failed or is not amenable to locoregional therapy
  • No de novo locoregional disease
  • No known brain metastases

PATIENT CHARACTERISTICS:

Age:

  • Adult

Performance status:

  • Zubrod 0-1

Life expectancy:

  • Not specified

Hematopoietic:

  • Absolute granulocyte count at least 1,500/mm^3
  • Platelet count at least 100,000/mm^3

Hepatic:

  • Bilirubin no greater than 1.5 times upper limit of normal (ULN)
  • SGOT or SGPT no greater than 2.5 times ULN
  • Alkaline phosphatase less than 2.5 times ULN

Renal:

  • Creatinine no greater than 1.5 mg/dL

Cardiovascular:

  • No recent myocardial infarction, unstable angina, or life-threatening arrhythmia

Other:

  • Not pregnant or nursing
  • Fertile patients must use effective contraception
  • No other malignancy within the past 5 years except adequately treated basal cell or squamous cell skin cancer, carcinoma in situ of the cervix, or stage I or II cancer in remission
  • No prior severe hypersensitivity reaction to drugs containing Cremophor EL
  • No active or uncontrolled infection
  • No severe psychiatric disorders

PRIOR CONCURRENT THERAPY:

Biologic therapy:

  • No prior neoadjuvant, adjuvant, or primary immunotherapy for advanced pancreatic cancer
  • No concurrent anticancer immunotherapy

Chemotherapy:

  • No prior neoadjuvant, adjuvant, or primary chemotherapy for advanced pancreatic cancer
  • No other concurrent anticancer chemotherapy

Endocrine therapy:

  • No prior neoadjuvant, adjuvant, or primary hormonal therapy for advanced pancreatic cancer
  • No concurrent anticancer hormonal therapy

Radiotherapy:

  • No prior neoadjuvant, adjuvant, or primary radiotherapy or chemoradiotherapy for advanced pancreatic cancer
  • Prior palliative radiotherapy allowed if at least 1 lesion remains outside of radiation field or at least 1 lesion has progressed since radiotherapy
  • No concurrent anticancer radiotherapy except palliative radiotherapy to non-target metastatic sites

Surgery:

  • At least 2 weeks since prior surgery for pancreatic cancer and recovered

Other:

  • No other concurrent anticancer therapy
  • No concurrent herbal or unconventional therapy (e.g., St. John's Wort)
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00016965

  Show 95 Study Locations
Sponsors and Collaborators
Southwest Oncology Group
Investigators
Study Chair: Robert P. Whitehead, MD University of Texas
  More Information

Additional Information:
Publications:
ClinicalTrials.gov Identifier: NCT00016965     History of Changes
Other Study ID Numbers: CDR0000068636, SWOG-S0107
Study First Received: June 6, 2001
Last Updated: June 20, 2013
Health Authority: United States: Federal Government

Keywords provided by National Cancer Institute (NCI):
stage II pancreatic cancer
stage III pancreatic cancer
recurrent pancreatic cancer
adenocarcinoma of the pancreas
stage IV pancreatic cancer

Additional relevant MeSH terms:
Pancreatic Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Neoplasms
Endocrine Gland Neoplasms
Digestive System Diseases
Pancreatic Diseases
Endocrine System Diseases

ClinicalTrials.gov processed this record on August 19, 2014